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Background: Lower urinary tract infections (LUTIs) are amongst the most common
community acquired infections with frequent antibiotic prescribing.
Objectives: To assess empiric antibiotic choice in different types of lower urinary tract
infections. We also aimed to identify determinants of ﬂuoroquinolone prescribing, as well
as to determine the rate of short antibiotic courses. The frequencies of executing
laboratory tests and recommending analgesics/anti-inﬂammatory drugs were
also assessed.
Methods: A prospective observational study was performed in 19 different Hungarian
primary care practices. Participating general practitioners (GPs) ﬁlled out data sheets for
each patient with a suspected urinary tract infection. Details of drug use were evaluated.
Comparison of different LUTI groups were made by descriptive statistics and univariate
analysis. Possible determinants of ﬂuoroquinolone prescribing were assessed by
logistic regression.
Results: Data sheets of 372 patients were analyzed. The majority of patients (68.82%)
had acute uncomplicated cystitis. While antibiotics were prescribed for almost every
patient (uncomplicated cases: 92.58%, complicated cases: 94.83%), analgesics/anti-
inﬂammatory drugs were recommended at a rate of 7.81% in uncomplicated, and 13.79%
in complicated cystitis cases. Ciproﬂoxacin was the most commonly prescribed
antibacterial agent in both types of cystitis. Short-term antibiotic therapy was
prescribed in one third of relevant cases. Logistic regression found a weak association
between ﬂuoroquinolone use and patient’s age and presence of complicating factors.
Conclusions: Many aspects of suboptimal cystitis management were identiﬁed (e.g.
unnecessarily broad spectra agents, too long antibiotic courses). In this study, patient
characteristics has weakly inﬂuenced ﬂuoroquinolone prescribing. Based on these results
there is considerable room for improvement in primary care antibiotic therapy of cystitis
in Hungary.
Keywords: lower urinary tract infection, management, antibiotic choice, ﬂuoroquinolone use, symptomatic
treatment, antibiotic stewardshipin.org December 2019 | Volume 10 | Article 14981
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To combat antibiotic resistance by lowering selection pressure,
rationalizing antibiotic use for the most frequent community
infections should be the key target of any antibiotic stewardship
programmes. Lower urinary tract infections (LUTIs) are among
the most commonly encountered illnesses in the ambulatory care
(e.g. almost half of all women will experience at least one episode
of cystitis during their lifetime), with consequently high
antibiotic prescribing (Bonkat et al., 2017; Tyrstrup et al., 2017;
Dumpis et al., 2018).
The classiﬁcation of urinary tract infections is based on the
affected anatomical site, and can be further stratiﬁed into
uncomplicated or complicated types based on the presence or
absence of complicating factors (e.g. diabetes mellitus) (Bonkat
et al., 2017; Reynard and Biers, 2019). Compared to
uncomplicated LUTI, the pathogen spectrum of complicated
LUTIs is much wider, and these bacteria are more likely to be
resistant to antibiotics, thus their empirical treatment tends to
utilize broad-spectrum antibiotics (Bonkat et al., 2017).
Unfortunately, the widely used coding system of diseases
(International Statistical Classiﬁcation of Diseases and Related
Health Problems (ICD) version 10) does not follow this
classiﬁcation, which limits the capabilities of database studies.
Previous drug utilisation studies based on the national health
care database of Hungary revealed suboptimal antibiotic use in
various infections (Juhasz et al., 2013; Matuz et al., 2015). The
aim of this study was to overcome the limitations of database
studies by exploiting clinical data that enables correct diagnosing
and further stratiﬁcation of cases. Based on these exact patient-
speciﬁc data we have assessed the empiric antibiotic choice in
complicated and uncomplicated LUTIs. Determinants of
ﬂuoroquinolone prescribing, the use of analgesics/anti-
inﬂammatory drugs and the frequency of laboratory urine
analysis (microbiological and chemical) were also evaluated.METHODS
A prospective observational study was conducted. General
practitioners (GPs) were invited and voluntarily participated,
without any ﬁnancial incentives. Twenty-ﬁve GPs accepted
participation (response rate: 51%), and 19 GPs (i.e. 19 different
primary care unit from various geographical location)
contributed throughout the study. GPs were asked to ﬁll in a
data sheet for all consecutive patients who ﬁrst presented with a
suspected urinary tract infection. The following data were
recorded: patient’s demography, drug allergy, presence of
complicating factors, clinical signs, history of urinary tract
infections in the previous year, performed lab tests and
treatments. Doctors’ specialty and experience (number of
practicing years) were derived from a public national database
(National Health Registration and Training Centre).
All patients over 16 years of age were eligible for inclusion.
Pregnant women, as well as cases with a suspected upper UTI
(pyelonephritis), or genital or sexually transmitted infection (e.g.
vaginal discharge) and cases where crucial data (e.g. prescribed/Frontiers in Pharmacology | www.frontiersin.org 2recommended therapy) were missing were excluded. Based on
the recorded signs/complaints and comorbidities we classiﬁed
each case as an uncomplicated or complicated lower urinary tract
infection according to the guideline of the European Urological
Association (Bonkat et al., 2017). The followings were considered
as complicating factors: male gender, diabetes mellitus, presence
of indwelling catheter/stent/tube, reconstruction of the urinary
tract, recent instrumentational intervention within the urinary
tract, functional/anatomical defects (e.g. obstruction,
incontinence), renal failure, kidney transplant, and
immunosuppression. In accordance with the widely accepted
deﬁnition, we deﬁned recurrent cystitis as a minimum of 2
infectious episodes within 6 months, or 3 infectious episodes
within a year (Bonkat et al., 2017). Antibiotics were classiﬁed
according to the WHO ATC (Anatomical-Therapeutic-
Chemical) index (version 2019). Short-term antibiotic course
was deﬁned as prescribing a single dose of fosfomycin, a 3-day-
course ofﬂuoroquinolone, a 5-day-course of beta-lactam and 5–7
days of nitrofurantoin therapy for uncomplicated cystitis
(Reynard and Biers, 2019).
Patient age, diagnostic measures and prescribed/
recommended therapy was compared in complicated and
uncomplicated cystitis by descriptive methods and univariate
analysis (Fischer’s and Welch’s tests). Potential inﬂuencing
factors of ﬂuoroquinolone prescribing (patient-speciﬁc
characteristics: age, gender, recurrent cystitis, presence of
complicating factors; GP-speciﬁc factors: years of practicing,
and specializations) were analyzed by logistic regression.
Statistical analyses were performed with the R statistical
software (version 3.5).
The study protocol was approved by the Regional Human
Medical Biology Research Ethical Board of the University of
Szeged, Hungary. The ethical approval did not allowed the
identiﬁcation and follow-up of patients, hence the therapeutic
outcomes could not be evaluated.RESULTS
Overall, 510 data sheets were collected. A total of 138 patients
were excluded (because of pregnancy, n = 11; genital/sexually
transmitted infection, n = 11; suspected kidney infection, n = 74;
missing data, n = 42), thus data sheets of 372 patients were
analyzed. Most patients were female (n = 342, 91.94%),
diagnosed with uncomplicated cystitis (n = 256, 68.82%).
Recurrent cystitis was present in one ﬁfth of patients (n =
71, 19.07%).
The average age of those diagnosed with complicated cystitis
was signiﬁcantly higher (64.44 ± 16.30 years vs. 48.12 ± 19.56),
and recurrent cystitis was also slightly more frequent in this
patient group. (Table 1).
Diagnostic measures and details of prescribed/recommended
therapies are summarized in Table 1 and Figure 1. Those with
complicated cystitis had higher age and higher rate of recurrent
infection (Table 1). With some exceptions, urine analysis was
extensively performed (in over 85% of cases) in both cystitis
types, while microbiological analysis of midstream urine wasDecember 2019 | Volume 10 | Article 1498
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and 21.55% in complicated cystitis, see Table 1). Antibiotic was
prescribed for 347 patients (93.28%), however, antibiotic
prescription rate of individual GPs ranged between 50.00% and
100 .00%. Ana lges i c s /ant i - inﬂammatory drugs was
recommended in 1 per 10 cases, while individual GP’s
recommendation rate ranged between 4.17% and 100.00%.
Using non-antibiotic treatment only (analgesic/anti-
inﬂammatory agent OR cranberry product OR herbal tea) was
recommended in as few as 11 cases (2.96%).
The most frequently prescribed antibiotics are shown in
Table 2. Although their rankings differed, the top ﬁve
antibiotics were the same in both types of cystitis.
C i p roﬂoxa c i n wa s th e mos t w id e l y u s ed ag en t .
Sulphamethoxazol-trimethoprim and fosfomycin were among
the most frequently prescribed antibacterials. Nitrofurantoin was
prescribed rarely (uncomplicated cystitis: 4 cases, complicated
cystitis: 6 cases). Guideline-recommended short-term antibiotic
course was initiated in ~30% of cases (Table 2).
Only evidence of a weak association was found between
patient characteristics and ﬂuoroquinolone prescribing (Table
3): younger adults and those with complicating factors tended to
be treated with ﬂuoroquinolones (odds ratio age: 0.98 yearly;
odds ratio complicating factors: 1.80). The frequency of
ﬂuoroquinolone prescribing varied substantially: some of theFrontiers in Pharmacology | www.frontiersin.org 3GPs did not prescribe these agents at all, while a single GP
prescribed this antibiotic in 85.71% of cystitis cases diagnosed in
her practice.DISCUSSION
The burden of urinary tract infections is high worldwide
(Foxman, 2014). However, ﬁeld studies to provide more insight
into the clinical practice of the outpatient management of UTIs
in adults are scarce (Martinez et al., 2007; Llor et al., 2011; Denes
et al., 2012; Butler et al., 2017; Dumpis et al., 2018). The main
objective of our study was to ﬁll in this gap by assessing empiric
antibiotic choice in different lower urinary tract infections (i.e.
complicated and uncomplicated cystitis). No signiﬁcant
difference has been observed in the antibiotic prescribing
patterns for the two types of cystitis.
As antibiotics are unambiguously superior to placebo for
urinary tract infections (Falagas et al., 2009), antibiotic use can
be considered optimal in every LUTI case. The rate of antibiotic
prescribing for LUTI in this study (over 90%) meets
international quality indicators (Adriaenssens et al., 2011; Le
Marechal et al., 2018) and correlates well with ﬁndings of
antibiotic utilisation studies for other countries, except the
Netherlands and Latvia where antibiotic prescription rate isTABLE 1 | General patient characteristics, diagnostics and therapeutics.
Uncomplicated cystitis N = 256 patients (100.00%) Complicated cystitis N = 116 patients (100.00%) P value
Gender Male – 30 (25.86%)
Female 256 (100.00%) 86 (74.14%) –
Age (years) Average ± SD 48.12 ± 19.56 64.44 ± 16.30 P < 0.0011
>65 years (%) 57 (22.27%) 62 (53.45%) P < 0.0012
Diabetes mellitus – 37 (31.90%) –
Functional/anatomical abnormality of the
urinary tract
– 34 (29.31%) –
Antibiotic prescribing 237 (92.58%) 110 (94.83%) P = 0.50762
Recurrent infection 33 (12.89%) 38 (32.76%) P < 0.0012
Dipstick test executed 216 (84.38%) 100 (86.21%) P = 0.7552
Microbiological urine analysis executed 39 (15.23%) 25 (21.55%) P = 0.1412
Analgesic use 20 (7.81%) 16 (13.79%) P = 0.08782
Short-term antibiotic use* 76 (32.07%) 32 (29.09%) P = 0.6192
Fluoroquinolone prescribing* 111 (46.84%) 54 (49.09%) P = 0.7292December 2019 | Volume 10 |1Welch’s two-sample t-test.
2Fisher’s exact test.
*Considering only those patients who were prescribed antibiotics (Uncomplicated cystitis: 237; Complicated cystitis: 110).FIGURE 1 | Antibiotic prescription at initial presentation.Article 1498
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tract infections in adults, respectively (Martinez et al., 2007; Llor
et al., 2011; Butler et al., 2017). The lower prescription rate in
these countries may be explained by the more frequent
application of delayed or conditional antibiotic prescribing
(Gagyor et al., 2012; Gagyor et al., 2015).
The use of analgesics/anti-inﬂammatory agents was found to
be limited, which can be explained by the lack of such
recommendations in national and international guidelines on
urological infections (Ministry of Health, 2010; Bonkat et al.,
2017). This is in contrast to the German guideline which only
recommends symptomatic treatment in uncomplicated cystitis
with mild to moderate symptoms (Kranz et al., 2017).
Short-course oral antibacterial treatment has been proven to
be as effective as long courses of antibiotics in the ambulatory
management of LUTIs (Dawson-Hahn et al., 2017). However, in
our study only 1 in 3 patients with uncomplicated cystitis
received a short-term antibiotic course, a ﬁnding similar to
other studies (Llor et al., 2011; Denes et al., 2012; Hawker
et al., 2014; Durkin et al., 2018; Phamnguyen et al., 2019). This
may be explained by the fact that pharmacies can dispense only
complete boxes of medicines instead of a certain number of
tablets actually needed,
The GPs in this study performed urine analysis (i.e. a urine
dipstick test) in the majority of cases in both types of cystitis. AsFrontiers in Pharmacology | www.frontiersin.org 4dipstick analysis is considered to have little added value when
typical urinary tract symptoms are present (Bonkat et al., 2017),
unnecessary testing can be presumed in some cases. On the other
hand, as dipstick analysis may also give information on the
causative bacterial class (i.e nitrite test is positive if
Enterobacteriaceae is present) its use can be justiﬁed.
Microbiological conﬁrmation of UTI is recommended in all
cases of complicated infections and recurrent urinary tract
symptoms (Bonkat et al., 2017). Unfortunately, microbiological
analysis was requested at a suboptimal rate (i.e only in 21.55% in
complicated LUTI) which can be partly explained by logistic
issues (lack of local laboratories and long distance between the
GP’s practice and laboratories) that hamper timely identiﬁcation
of the pathogens (Hajdu et al., 2009). The Flexicult system (Bates
et al., 2014; Hullegie et al., 2017), aimed for point-of-care
diagnoses of UTI and susceptibility testing of urinary
pathogens is not used in Hungary due to the lack of
reimbursement (and also this is the case for other point-of-
care tests utilized in other e.g. Scandinavian countries).
The pattern of antibiotic use was similar for both uncomplicated
and complicated cystitis, and showed a high dominance of
ﬂuoroquinolones. The use of ﬂuoroquinolones in UTI varies
greatly in the literature, but none of the European countries
(except for a non-recent publication from France)(Denes et al.,
2012) reported such a high ratio of ﬂuoroquinolone prescribing. InTABLE 3 | Fluoroquinolone prescribing with regard to patient- and GP-speciﬁc factors.
No ﬂuoroquinolone
prescribed
N = 182 patients (100.00%)
Fluoroquinolone therapy
prescribed
N = 165 patients (100.00%)
Logistic regression
OR (95% CI) P value
Gender Female 170 (93.41%) 150 (90.91%) baseline
Male 12 (6.59%) 15 (9.09%) 1.52 (0.67–3.46) 0.319
Age (years) Average ± SD 56.40 ± 19.51 50.95 ± 20.38 0.98 (0.97–0.99) 0.002
Complicating factors 49 (26.92%) 50 (30.30%) 1.80 (1.03–3.12) 0.038
Recurrent LUTI 39 (21.43%) 28 (16.97%) 0.65 (0.36–1.17) 0.153
GP’s experience 10–20 years of practice 40 (21.98%) 30 (18.18%) Baseline
>20 years of practice 142 (78.02%) 135 (81.82%) 1.35 (0.76–2.37) 0.309
GP’s specialty Only GP specialty 85 (46.70%) 73 (44.24%) Baseline
GP+other specialty 97 (53.30%) 92 (55.76%) 1.10 (0.69–1.75) 0.684December 2019 | Volume 10 | Article 1498OR, Odds ratio; 95% CI, conﬁdence interval; logistic regression model constant: 0.52; p = 0.177.TABLE 2 | Most frequently prescribed systemic antibiotics.
Uncomplicated cystitis (N = 256 patient; 100.00%) Complicated cystitis (N = 116 patient; 100.00%)
Active agent patient % Active agent patient %
1 Ciproﬂoxacin 55 21.48 Ciproﬂoxacin 30 25.86
2 Fosfomycin 48 18.75 Norﬂoxacin 22 18.97
3 Norﬂoxacin 48 18.75 SMX-TMP 15 12.93
4 SMX-TMP 30 11.72 Fosfomycin 13 11.21
AMC 14 5.47 Cefuroxime 9 7.76
5 Cefuroxime 14 5.47AMC, amoxicillin-clavulanic acid.
SMX-TMP, sulphamethoxazol-trimethoprim.
Benko et al. Treatment of CystitisNorway, Denmark, Sweden and the Netherlands the use of
ﬂuoroquinolone agents were reported to be below 10%, thanks to
strict and well-functioning antibiotic stewardships (Agdestein et al.,
2011; Tyrstrup et al., 2017; Dumpis et al., 2018; Holm et al., 2019).
In Latvia and Lithuania, ﬂuoroquinolones are reported to be used in
23% and 25% of uncomplicated UTI cases, respectively (Dumpis
et al., 2018). Similar rates for ﬂuoroquinolone use in cystitis (22%)
was reported for Belgium (Tyrstrup et al., 2017). In contrast, a
relatively frequent ﬂuoroquinolone use (30% of all cases) in
uncomplicated UTI has been reported from the US recently, and
this rate was even higher in the preceding years (Durkin et al., 2018;
Cowart et al., 2019). The decreasing trend is explained by the
publication of an FDA black box warning on ﬂuoroquinolones in
2016 (Cowart et al., 2019). In Hungary no up-to-date guidelines are
available for the antibiotic prescribing in UTIs, and the previous
guidelines (that still pop-up as the ﬁrst hit in a google search)
recommended the use of ﬂuoroquinolones in all types of UTIs
(Nephrology, 2006; Ministry of Health, 2010). Thus, in fact, our
ﬁndings are not surprising, but the high ﬂuoroquinolone
dominance is unwanted, especially if we consider the 2018 safety
review-based restrictions (European Medicines Agency, 2019) of
the European Commission on ﬂuoroquinolone prescribing (valid
since 11 March 2019 in all EU countries).
Only weak determinants of ﬂuoroquinolone prescribing were
identiﬁed: younger age and presence of complicating factors were
found to inﬂuence the rate of ﬂuoroquinolone therapy. As
ﬂuoroquinolones have a high potential to generate resistance
(Schito et al., 2009), and the ﬂuoroquinolone resistance of E.coli
already exceeds 20% in urine samples in Hungary (Hungarian
National Bacteriological Surveillance Management Team, National
Centre for Epidemiology), the high use of ﬂuoroquinolones
demonstrated in our study is clearly worrisome. Qualitative
studies are needed to better explore the high differences in
ﬂuoroquinolone prescribing rate of individual GPs.
Patients with uncomplicated cystitis were prescribed
fosfomycin in 18.75% of all cases and nitrofurantoin in only 4
cases which is suboptimal according to international quality
indicators (Adriaenssens et al., 2011). These data are also
regarded as worrisome, as these two drugs have their
renaissance in the treatment of uncomplicated LUTI due to
their preserved effectiveness (Gardiner et al., 2019). On the other
hand, these agents (i.e. fosfomycin and nitrofurantoin) should be
avoided in complicated cystitis due to their lack of activity
against the potential uropathogens in these cases (Bonkat et al.,
2017). Nevertheless, fosfomycin was among the top ﬁve agents
prescribed for complicated cystitis.
Regarding sulphamethoxazol-trimethoprim (SMX-TMP), its
ﬁrst line use should be limited to uncomplicated cases, and only
when local resistance patterns permit this choice. In Hungary,
the prevalence of E. coli strains resistant to sulphamethoxazol-
trimethoprim is reported to be above 20% (Hungarian National
Bacteriological Surveillance Management Team National Centre
for Epidemiology), but considering that resistance surveillance
systems may overestimate resistance patterns (Schmiemann
et al., 2012), SMX-TMP use can be accepted as a rational
choice in uncomplicated cystitis.Frontiers in Pharmacology | www.frontiersin.org 5The strengths of our survey include the ability to exploit
clinical data. Also, by applying common diagnostic and
classiﬁcation criteria, misclassiﬁcation bias could be avoided,
and the choice of antibiotic could be justiﬁed. A limitation of our
study is the voluntary participation of GPs. As volunteering GPs
may be more concerned about their rational antibiotic
prescribing practices, the global prescribing patterns in
Hungary might be more suboptimal than presented in this study.CONCLUSIONS
Our study has found similar patterns of antibiotic use in both
types of cystitis (with high ﬂuoroquinolone dominance), and
identiﬁed suboptimal antibiotic use from various aspects. Patient
characteristics has weakly inﬂuenced ﬂuoroquinolone
prescribing More prudent use of antibiotics in lower urinary
tract infections is urgently needed.DATA AVAILABILITY STATEMENT
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